This article is a correction to:
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
Tetiana Yatsenko1,2
Ricardo Rios3
Tatiane Nogueira3
Yousef Salama4
Satoshi Takahashi5
Yoko Tabe1
Toshio Naito1Kazuhisa Takahashi1,6Koichi Hattori7,8*†
Beate Heissig1*†- 1Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University School of Medicine, Tokyo, Japan
- 2Department of Enzymes Chemistry and Biochemistry, Palladin Institute of Biochemistry of the National Academy of Science of Ukraine, Kyiv, Ukraine
- 3Institute of Computing, Federal University of Bahia, Salvador, Bahia, Brazil
- 4An-Najah Center for Cancer and Stem Cell Research, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
- 5Division of Clinical Precision Research Platform, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan
- 6Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan
- 7Center for Genome and Regenerative Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan
- 8Department of Hematology/Oncology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan
A Corrigendum on
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
By Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Tabe Y, Naito T, Takahashi K, Hattori K and Heissig B (2024) Front. Immunol. 14:1299792. doi: 10.3389/fimmu.2023.1299792
In the published article, there was an error in the author list, and author Yousef Salama, along with their affiliation, was erroneously excluded. The corrected author list and affiliations appear below.
Tetiana Yatsenko1,2, Ricardo Rios3, Tatiane Nogueira3, Yousef Salama4, Satoshi Takahashi5, Yoko Tabe1, Toshio Naito1, Kazuhisa Takahashi1,6, Koichi Hattori 7,8* and Beate Heissig 1*
1Department of Research Support Utilizing Bioresource Bank, Graduate School of Medicine, Juntendo University School of Medicine, Tokyo, Japan
2Department of Enzymes Chemistry and Biochemistry, Palladin Institute of Biochemistry of the National Academy of Science of Ukraine, Kyiv, Ukraine
3Institute of Computing, Federal University of Bahia, Salvador, Bahia, Brazil
4 An-Najah Center for Cancer and Stem Cell Research, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine;
5Division of Clinical Precision Research Platform, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan
6Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan
7Center for Genome and Regenerative Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan
8Department of Hematology/Oncology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
In the published article, there was an error in the Author Contribution section. Due to the fact author Yousef Salama was erroneously excluded, their contributions were not included in this section. The corrected Author Contribution section appears below.
Author contributions
BH: Conceptualization, Funding acquisition, Writing – original draft. RR: Formal analysis, Methodology, Software, Writing – review & editing. TNo: Formal analysis, Methodology, Software, Writing – review & editing. YS: Data curation, Writing – review & editing. ST: Funding acquisition, Writing – review & editing. YT: Resources, Writing – review & editing. TNa: Resources, Writing – review & editing. KT: Resources, Writing – review & editing. KH: Conceptualization, Funding acquisition, Writing – review & editing. TY: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – review & editing, Writing – original draft.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: COVID-19, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, interleukin-6, fibrinolysis, thrombosis, C-reactive protein, respiratory distress syndrome
Citation: Yatsenko T, Rios R, Nogueira T, Salama Y, Takahashi S, Tabe Y, Naito T, Takahashi K, Hattori K and Heissig B (2024) Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19. Front. Immunol. 15:1390698. doi: 10.3389/fimmu.2024.1390698
Received: 23 February 2024; Accepted: 01 March 2024;
Published: 13 March 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Yatsenko, Rios, Nogueira, Salama, Takahashi, Tabe, Naito, Takahashi, Hattori and Heissig. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Beate Heissig, heissig@juntendo.ac.jp; Koichi Hattori, khattori@juntendo.ac.jp
†ORCID: Koichi Hattori, orcid.org/0000000313800704
Beate Heissig, orcid.org/0000-0002-0348-5934